Orphan drug designation for novel drug CB-5083 as a treatment for myeloma

Cleave Biosciences, the US biotechnology company, has announced that its lead drug candidate CB-5083 has been granted orphan drug designation by the US Food and Drug Administration (FDA). CB-5083 is a first-in-class oral inhibitor of p97, an enzyme involved in key aspects of protein homeostasis including non-proteasomal protein degradation. Efficient removal of protein is crucial…

Details

Study shows thalidomide equally as effective as lenalidomide upfront

A study, published recently in Blood, has shown that older/less fit newly diagnosed myeloma patients treated with either melphalan, prednisolone and thalidomide (MPT-T) or melphalan, prednisolone and lenalidomide (mPR-R)┬áhad similar overall response rates, progression-free survival and overall survival. In this Phase III trial involving 306 patients with a median age of 75.7 years,┬ámedian progression-free survival…

Details